Proactive Investors - Run By Investors For Investors

Rex Bionics PLC inks US Army deal

The agreement is a precursor to design modifications to the mobility system to allow it be used in this way.
Rex Bionics PLC inks US Army deal
The Rex mobility aid may be used to help rehabilitate American soldiers.


Rex Bionics PLC (LON:RXB) has signed an outline deal with the US Army, which is looking to the use the company’s robotic exoskeleton to rehabilitate soldiers that have lost lower limbs.

The agreement is a precursor to design modifications to the mobility system to allow it be used in this way.

The Rex equipment, as well as helping the disabled walk upright, is being developed to aid physiotherapy for people with spinal cord and traumatic brain injury.

"We are delighted with this opportunity and the recognition of REX's unique design features,” said chief executive Crispin Simon.

“It is a strong start for our strategy to take REX into acute as well as chronic care management."

The terms of its tie up are covered in what’s called Materiel Transfer Agreement with the United States Army Medical Research and Materiel Command.

In the same release Rex made reference an announcement late last year by the US Department of Veterans Affairs.

The VA issued a national policy for the “evaluation, training and procurement” of the ReWalk Personal exoskeleton, created by Rewalk Robotics.

“The VA policy does not directly relate to the REX robotic mobility system,” Rex told investors.

“But the directors of Rex Bionics believe that there will be US veterans for whom the Rex system will be the only, or the preferred, option (for Soldier Members, with lower limb loss, for example) and that the VA announcement is therefore positive for the long-term prospects for Rex Bionics.” 

He said the equipment, after slight modifications, would be used on frontline field hospitals treating injuries sustained by roadside bombs.

Simon also added that he would not rule out a collaboration with other developers.

Share price was down 8% to 40.00p.

View full RXB profile View Profile

Rex Bionics PLC Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use